Franklin Resources Inc. lowered its holdings in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,195,703 shares of the biotechnology company’s stock after selling 227,474 shares during the quarter. Franklin Resources Inc. owned 12.69% of Heron Therapeutics worth $148,357,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in HRTX. Alyeska Investment Group L.P. raised its stake in shares of Heron Therapeutics by 9.5% in the third quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock valued at $12,188,000 after acquiring an additional 65,260 shares during the period. Deltec Asset Management LLC purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at $2,118,000. Swiss National Bank raised its stake in shares of Heron Therapeutics by 25.5% in the fourth quarter. Swiss National Bank now owns 98,500 shares of the biotechnology company’s stock valued at $1,783,000 after acquiring an additional 20,000 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Heron Therapeutics by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock valued at $482,000 after acquiring an additional 8,135 shares during the period. Finally, Claraphi Advisory Network LLC purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at $335,000.
HRTX has been the topic of several recent analyst reports. BidaskClub downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Mizuho reissued a “buy” rating and issued a $28.00 target price on shares of Heron Therapeutics in a research note on Friday, December 8th. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research note on Friday, March 2nd. Finally, Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $30.08.
Heron Therapeutics Inc (HRTX) opened at $24.05 on Wednesday. Heron Therapeutics Inc has a 12 month low of $12.70 and a 12 month high of $24.80.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). The company had revenue of $10.05 million during the quarter, compared to analysts’ expectations of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. research analysts anticipate that Heron Therapeutics Inc will post -2.56 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Franklin Resources Inc. Lowers Holdings in Heron Therapeutics Inc (HRTX)” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/03/14/franklin-resources-inc-lowers-holdings-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.